Suppression by progabide of ethanol withdrawal syndrome in rats.

Article Details

Citation

Copy to clipboard

Fadda F, Mosca E, Meloni R, Gessa GL

Suppression by progabide of ethanol withdrawal syndrome in rats.

Eur J Pharmacol. 1985 Mar 12;109(3):321-5.

PubMed ID

2985405 [ View in PubMed

]

Abstract

Progabide, a specific and clinically used GABA receptor agonist, was tested for its ability to suppress ethanol withdrawal syndrome. Male rats were rendered physically dependent on ethanol by feeding for 12 days on a liquid diet in which ethanol isocalorically replaced dextrose. Progabide (100-400 mg/kg i.p.), administered 8 h after ethanol was withdrawn, produced a dose-related inhibition of both tremors and audiogenically induced seizures. A single dose of 400 mg/kg of progabide completely suppressed all ethanol withdrawal reactions. Seizures were more sensitive to the drug than tremors. The results support the view that a decrease in GABA transmission plays a role in ethanol withdrawal symptoms and suggest that progabide may be tested as a possible treatment of ethanol withdrawal syndrome in man.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Progabide	Gamma-aminobutyric acid receptor subunit alpha-1	Protein	Humans	Yes	Agonist	Details
Progabide	Gamma-aminobutyric acid type B receptor subunit 1	Protein	Humans	Yes	Agonist	Details